The real show of life - MBI story featured in major brazilian tv show
On October 5th, the story of our founder, Fernando Goldsztein, was featured on Fantástico — a brazilian Sunday night TV show with a huge audience that has been on the air for over 50 years.
MBI: Synergy and collaboration among the best researchers to solve the medulloblastoma puzzle
Thanks to our unique model, two trials were approved in record time – with a focus on sparing kids from toxic treatments and moving closer to a cure for the most common brain cancer in children
MBI: Synergy and collaboration among the best researchers.
Thanks to our unique model, two trials approved in record time – sparing kids from toxic treatments and moving closer to a cure for the most common brain cancer in children.
MBI: Synergy and collaboration among the best researchers.
Thanks to our unique model, two trials approved in record time – sparing kids from toxic treatments and moving closer to a cure for the most common brain cancer in children.
The
Medulloblastoma
Initiative
The Medulloblastoma Initiative (MBI) was established in 2021 to materialize the vision shared by Brazilian entrepreneur Fernando Goldsztein and Dr. Roger J. Packer, based at the Children’s National Hospital in Washington DC.. The MBI raises private resources that are channeled to the research on Group 4 medulloblastoma developed by the Cure Group 4 Consortium — which includes 16 laboratories installed in the US, Canada, and Germany. Medulloblastoma is the most common pediatric brain cancer. Nevertheless, the treatment protocol used today has not changed since the 1980s.
In addition to not curing a large proportion of the children affected by medulloblastoma, current treatments impose severe, life-lasting side effects to the children who survive. And this is why the MBI works to connect private donors to great scientists.
Join us — “whoever saves one life saves the world entire”.
MATCHPOINT:
Duane Mitchell, MD, PhD, co-director of the University of Florida’s Preston A. Wells Jr. Center for Brain Tumor Therapy, leads the MATCHPOINT trial. The therapy harnesses adoptive cell therapy (ACT), which programs a patient’s T cells (white blood cells critical to the body) to seek and destroy cancer cells. In a previous study (ReMATCH), Dr. Mitchell’s lab demonstrated ACT’s significant promise as a safe and effective treatment for relapsed medulloblastoma. One patient saw a nearly total elimination of widespread metastatic disease.
“The ultimate goal is we want to cure kids”
SCIENTIFIC INSTITUTIONS
INTEGRATING THE CONSORTIUM
IN THE MEDIA
International recognition marks an important milestone for the MBI. Fox News, through anchor Bret Baier — former chief White House and Pentagon correspondent — highlighted MBI’s mission to accelerate scientific discoveries and transform the lives of thousands of children.
On August 7, MBI gained international recognition when it was featured on MSNBC — one of the leading news networks in the United States — during Morning Joe, a national broadcast.
The Medulloblastoma Initiative (MBI) was featured on the CNN Brasil website, in a report that highlights the impact of
our innovative model for accelerating science.
On June 7, we had the honor of seeing a letter from our founder published in The Washington Post, one of the most respected newspapers in the United States…
MBI has been highlighted by one of the most prestigious institutions in the world, MIT – Massachusetts Institute of Technology…
This month, the II Conexões de Valor will take place, this project that had its first edition in 2023 and was born from the inspiration of the PUCRS Alumnus…
Every year, about 25,000 children worldwide are diagnosed with medulloblastoma, the most common type of childhood brain cancer. It primarily affects children aged 4 to 9…
After receiving the news that his son had cancer, Brazilian businessman Fernando Goldsztein created an innovative research model and, in record time, secured approval…
In June 2024, VEJA magazine published the statement given by Fernando Goldsztein, Founder of The Medulloblastoma Initiative, to journalist Simone Blanes.
Journalist Kelly Matos, from Zero Hora—one of Brazil’s leading newspapers—wrote a heartfelt column about cancer cures and the work of MBI
“I intend to work for the rest of my life for pediatric cancer. I am sure that this group of scientists will find the cure for medulloblastoma…
Jennifer Griffin (Fox News) reports on Fernando Goldsztein and the Medulloblastoma Initiative’s efforts to fight the most common form of pediatric brain cancer
Created by a businessman from Rio Grande do Sul, MBI searches for funds to finance the research to combat medulloblasma. The global initiative raised USD 10 million in two years. In six months, the consortium of laboratories financed by the project has already made significant discoveries.
What is medulloblastoma? What are the late effects of treatment? Ana Lourenço addresses these topics and tells how MBI came about and its mission to find a cure for medulloblastoma. “We have to persevere and keep going. We can’t give up.” says Fernando Goldsztein, founder of the project.
The Medulloblastoma Initiative was created to save the son of entrepreneur Fernando Goldsztein and another 15,000 children every year.
Fernando Goldsztein, MBI founder, tells the reasons for creating the project and how it has grown exponentially since its foundation. “A parent’s heartfelt thought: children should be immune to cancer!”, he declares.
The columnist Daniel Scola talks about his experience at the 1st International Symposium on Pediatric Neuro-Oncology, reporting his experience as a survivor and commenting on the importance that initiatives such as MBI have in the development of new treatments.
On Father’s Day, journalist Cláudia Colucci and Folha de S.Paulo tell the story of MBI, which supports a consortium of laboratories seeking a cure for medulloblastoma — an initiative born from the experience of a father and a child facing this cancer.
O relato de Fernando Goldsztein sobre a MBI foi publicado na newsletter da MIT Sloan, a escola de negócios do prestigiado Massachusetts Institute of Technology. Não por acaso, a história da MBI entrou para a lista das 10 melhores histórias de ex-alunos da MIT Sloan Business School em 2022.
The research supported the MBI to find a cure of medulloblastoma, the most common brain cancer in children, will soon begin clinical trials. For this new stage, in the coming months, MBI will seek $7 million in private donations.
“My son’s illness changed my life,” says Fernando Goldsztein, MBI founder. He left an executive position at a large real estate company to support research aimed at finding a cure for medulloblastoma.
How did MBI start, and what difference can philanthropic donations make in advancing scientific research? “I never imagined the impact could be so significant,” the founder of MBI told Brazil Journal.
In 2021, Brazilian journalist Daniel Scola was diagnosed with medulloblastoma. “I was among those saved thanks to science,,” he wrote when reporting about the MBI, “an innovative project that will greatly contribute to health globally”.
GOING ON AT MBI
MBI on The Lead in Peds
Dr. Roger Packer, Senior Director of the Center for Neuroscience and Behavioral Medicine at Children’s National Hospital (USA), joined the The Lead in Peds podcast on September 24 to discuss recent advances in therapies for pediatric brain
MBI innovates once again with a new partnership: Einstein Hospital Israelita
The Medulloblastoma Initiative (MBI) announces a new partnership with Einstein Hospital Israelita, a collaboration that brings together two leading institutions in science and innovation with a shared purpose: to accelerate progress in the research and treatment of
MBI mentioned by Exame
One of the most respected magazines in the country mentioned MBI in a report about scientific advances in the treatment of medulloblastoma. With more than 50 years of history, Exame is a national reference in economic, scientific,